Evidence map›Paper›PMID 32633860›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2020

Safety of Plasma Infusions in Parkinson's Disease.

Jordan E Parker, Amaris Martinez, Gayle K Deutsch, Varsha Prabhakar, Melanie Lising, Kristopher I Kapphahn, Chioma M Anidi, Raumin Neuville, Maria Coburn, Neil Shah and 1 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02968433 (The Stanford Parkinson's Disease Plasma), which is not on this map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02968433 phase1completednot on this map

The Stanford Parkinson's Disease Plasma (SPDP) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Moderate Parkinson's Disease

TypeinterventionalSponsorStanford UniversityRan2016 to 2019Enrolled16ConditionsParkinson Disease(PD)ArmsInfusions of young plasma
3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Jordan E ParkerDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
Amaris MartinezDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
Gayle K DeutschDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
Varsha PrabhakarMiller School of Medicine, University of Miami, Miami, Florida, USA.
Melanie LisingDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
Kristopher I KapphahnQuantitative Sciences Unit, Stanford University School of Medicine, Stanford, California, USA.
Chioma M AnidiSchool of Medicine, University of Michigan, Ann Arbor, Michigan, USA.
Raumin NeuvilleSchool of Medicine, University of California, Irvine, Irvine, California, USA.
Maria CoburnDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.
Neil ShahDepartment of Pathology, Stanford University School of Medicine, Stanford, California, USA.
Helen M Bronte-StewartDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.ORCID 0000-0002-1839-4541
Stanford University · USUniversity of California, Irvine · USUniversity of Miami · USUniversity of Michigan · US

Funding

Private philanthropic donation
6 · The paper itself

Abstract

backgroundYoung plasma infusions have emerged as a potential treatment for neurodegenerative disease, and convalescent plasma therapy has been used safely in the management of viral pandemics. However, the effect of plasma therapy in Parkinson's disease (PD) is unknown.

objectivesThe objective of this study was to determine the safety, tolerability, and feasibility of plasma infusions in people with PD.

methodsA total of 15 people with clinically established PD, at least 1 cognitive complaint, and on stable therapy received 1 unit of young fresh frozen plasma twice a week for 4 weeks. Assessments and adverse effects were performed/reported on and off therapy at baseline, immediately after, and 4 weeks after the infusions ended. Adverse effects were also assessed during infusions. The primary outcomes were safety, tolerability, and feasibility. Exploratory outcomes included Unified Parkinson's Disease Rating Scale Part III off medication, neuropsychological battery, Parkinson's Disease Questionnaire-39, inflammatory markers (tumor necrosis factor-α, interleukin-6), uric acid, and quantitative kinematics.

resultsAdherence rate was 100% with no serious adverse effects. There was evidence of improvement in phonemic fluency (P = 0.002) and in the Parkinson's Disease Questionnaire-39 stigma subscore (P = 0.013) that were maintained at the delayed evaluation. Elevated baseline tumor necrosis factor-α levels decreased 4 weeks after the infusions ended.

conclusionsYoung fresh frozen plasma was safe, feasible, and well tolerated in people with PD, without serious adverse effects and with preliminary evidence for improvements in phonemic fluency and stigma. The results of this study warrant further therapeutic investigations in PD and provide safety and feasibility data for plasma therapy in people with PD who may be at higher risk for severe complications of COVID-19. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

PlasmaAgedAged, 80 and overAgingAntiparkinson AgentsBiomechanical PhenomenaBlood Component TransfusionCognition DisordersCombined Modality TherapyCOVID-19Deep Brain StimulationFeasibility StudiesFemaleHumansInterleukin-6MaleAntiparkinson AgentsIL6 protein, humanInterleukin-6Tumor Necrosis Factor-alphainfusionsParkinson's diseaseplasmayoung plasma

Identifiers

PMID32633860
PMCPMC7361360
OpenAlexW3039146275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.